Table 1.
Patient Characteristics
| Breast Cancer (N = 2,095,339) | Melanoma (N = 472,611) | Colon Cancer (N = 627,090) | Kidney Cancer (N = 407,627) | Non-Small Cell Lung Cancer (N = 1,060,774) | Small Cell Lung Cancer (N = 164,864) | |
|---|---|---|---|---|---|---|
| Brain metastases at diagnosis | ||||||
| No | 2088262 (99.7%) | 465699 (98.5%) | 625084 (99.7%) | 402508 (98.7%) | 950988 (89.7%) | 138505 (84.0%) |
| Yes | 7077 (0.3%) | 6912 (1.5%) | 2006 (0.3%) | 5119 (1.3%) | 109786 (10.3%) | 26359 (16.0%) |
| Patient age | ||||||
| Mean (SD) | 61.3 (13.0) | 63.1 (15.5) | 67.3 (14.1) | 62.9 (13.8) | 68.8 (10.6) | 67.5 (9.85) |
| Median [Min, Max] | 62.0 [0, 90.0] | 65.0 [0, 90.0] | 68.0 [0, 90.0] | 64.0 [0, 90.0] | 69.0 [0, 90.0] | 68.0 [19.0, 90.0] |
| Patient sex | ||||||
| Male | 17829 (0.9%) | 275382 (58.3%) | 309380 (49.3%) | 255114 (62.6%) | 541647 (51.1%) | 78009 (47.3%) |
| Female | 2077510 (99.1%) | 197229 (41.7%) | 317710 (50.7%) | 152513 (37.4%) | 519127 (48.9%) | 86855 (52.7%) |
| Patient race | ||||||
| White | 1714434 (81.8%) | 460958 (97.5%) | 512225 (81.7%) | 339784 (83.4%) | 899491 (84.8%) | 147441 (89.4%) |
| Black | 249881 (11.9%) | 2443 (0.5%) | 81539 (13.0%) | 48484 (11.9%) | 116735 (11.0%) | 13119 (8.0%) |
| Other | 111696 (5.3%) | 4092 (0.9%) | 28384 (4.5%) | 15600 (3.8%) | 37840 (3.6%) | 3346 (2.0%) |
| Unknown | 19328 (0.9%) | 5118 (1.1%) | 4942 (0.8%) | 3759 (0.9%) | 6708 (0.6%) | 958 (0.6%) |
| Tumor grade | ||||||
| Grade 1 | 357294 (17.1%) | 1162 (0.2%) | 60498 (9.6%) | 28927 (7.1%) | 70542 (6.7%) | 252 (0.2%) |
| Grade 2 | 735946 (35.1%) | 633 (0.1%) | 308482 (49.2%) | 115569 (28.4%) | 197357 (18.6%) | 526 (0.3%) |
| Grade 3 | 537971 (25.7%) | 1342 (0.3%) | 83118 (13.3%) | 69809 (17.1%) | 245370 (23.1%) | 13523 (8.2%) |
| Grade 4 | 8065 (0.4%) | 534 (0.1%) | 16002 (2.6%) | 25634 (6.3%) | 9477 (0.9%) | 19460 (11.8%) |
| Other/unknown | 456063 (21.8%) | 468940 (99.2%) | 158990 (25.4%) | 167688 (41.1%) | 538028 (50.7%) | 131103 (79.5%) |
| Clinical T stage | ||||||
| T0 | 9911 (0.5%) | 5971 (1.3%) | 3658 (0.6%) | 777 (0.2%) | 4692 (0.4%) | 1573 (1.0%) |
| T1 | 825262 (39.4%) | 127481 (27.0%) | 60495 (9.6%) | 202831 (49.8%) | 290748 (27.4%) | 23113 (14.0%) |
| T2 | 361479 (17.3%) | 49305 (10.4%) | 22571 (3.6%) | 40606 (10.0%) | 236697 (22.3%) | 32922 (20.0%) |
| T3 | 73295 (3.5%) | 27783 (5.9%) | 61470 (9.8%) | 29276 (7.2%) | 130508 (12.3%) | 22933 (13.9%) |
| T4 | 57510 (2.7%) | 19508 (4.1%) | 30053 (4.8%) | 5633 (1.4%) | 150584 (14.2%) | 39347 (23.9%) |
| Other/unknown | 767882 (36.6%) | 242563 (51.3%) | 448843 (71.6%) | 128504 (31.5%) | 247545 (23.3%) | 44976 (27.3%) |
| Clinical N stage | ||||||
| N0 | 1468750 (70.1%) | 352327 (74.5%) | 350310 (55.9%) | 291365 (71.5%) | 445229 (42.0%) | 22649 (13.7%) |
| N1 | 198121 (9.5%) | 8611 (1.8%) | 50496 (8.1%) | 17187 (4.2%) | 69733 (6.6%) | 11847 (7.2%) |
| N2 | 32773 (1.6%) | 3406 (0.7%) | 17090 (2.7%) | 1458 (0.4%) | 243324 (22.9%) | 70431 (42.7%) |
| N3 | 23396 (1.1%) | 2734 (0.6%) | 0 (0%) | 94 (0.0%) | 97859 (9.2%) | 27861 (16.9%) |
| Other/unknown | 372299 (17.8%) | 105533 (22.3%) | 209194 (33.4%) | 97523 (23.9%) | 204629 (19.3%) | 32076 (19.5%) |
| Bone metastases at diagnosis | ||||||
| No | 2034879 (97.1%) | 468483 (99.1%) | 619857 (98.8%) | 387757 (95.1%) | 907643 (85.6%) | 129079 (78.3%) |
| Yes | 60006 (2.9%) | 3907 (0.8%) | 6859 (1.1%) | 19586 (4.8%) | 150487 (14.2%) | 34967 (21.2%) |
| Other/unknown | 454 (0.0%) | 221 (0.0%) | 374 (0.1%) | 284 (0.1%) | 2644 (0.2%) | 818 (0.5%) |
| Lung metastases at diagnosis | ||||||
| No | 2067340 (98.7%) | 463450 (98.1%) | 598758 (95.5%) | 379222 (93.0%) | 940839 (88.7%) | 144786 (87.8%) |
| Yes | 26841 (1.3%) | 8871 (1.9%) | 26960 (4.3%) | 27825 (6.8%) | 112296 (10.6%) | 17843 (10.8%) |
| Other/unknown | 1158 (0.1%) | 290 (0.1%) | 1372 (0.2%) | 580 (0.1%) | 7639 (0.7%) | 2235 (1.4%) |
| Liver metastases at diagnosis | ||||||
| No | 2072684 (98.9%) | 467899 (99.0%) | 531661 (84.8%) | 397322 (97.5%) | 987762 (93.1%) | 116882 (70.9%) |
| Yes | 21935 (1.0%) | 4491 (1.0%) | 94815 (15.1%) | 9925 (2.4%) | 69450 (6.5%) | 47216 (28.6%) |
| Other/unknown | 720 (0.0%) | 221 (0.0%) | 614 (0.1%) | 380 (0.1%) | 3562 (0.3%) | 766 (0.5%) |
| ER (SSF1) | ||||||
| Yes | 1456995 (69.5%) | |||||
| No | 296930 (14.2%) | |||||
| Other/unknown | 341414 (16.3%) | |||||
| PR (SSF2) | ||||||
| Yes | 1266397 (60.4%) | |||||
| No | 463133 (22.1%) | |||||
| Other/unknown | 365809 (17.5%) | |||||
| HER2 (SSF15) | ||||||
| Yes | 216932 (10.4%) | |||||
| No | 1201940 (57.4%) | |||||
| Other/unknown | 676467 (32.3%) | |||||
| Ulceration (SSF2) | ||||||
| Yes | 52677 (11.1%) | |||||
| No | 319656 (67.6%) | |||||
| Other/unknown | 100278 (21.2%) | |||||
| Tumor Histology a | ||||||
| Type 1 | 580274 (92.5%) | |||||
| Type 2 | 46816 (7.5%) | |||||
| CEA (SSF1) | ||||||
| Positive | 152173 (24.3%) | |||||
| Negative | 161662 (25.8%) | |||||
| Other/unknown | 313255 (50.0%) | |||||
| Tumor Histology b | ||||||
| Type 1 | 71623 (17.6%) | |||||
| Type 2 | 288011 (70.7%) | |||||
| Type 3 | 47993 (11.8%) | |||||
| Sarcomatoid Features (SSF4) | ||||||
| Yes | 11391 (2.8%) | |||||
| No | 257570 (63.2%) | |||||
| Other/unknown | 138666 (34.0%) | |||||
| Fuhrman Nuclear Grade (SSF6) | ||||||
| 1 | 28171 (6.9%) | |||||
| 2 | 125887 (30.9%) | |||||
| 3 | 69877 (17.1%) | |||||
| 4 | 19545 (4.8%) | |||||
| Other/unknown | 164147 (40.3%) | |||||
| Tumor Histology c | ||||||
| Adenocarcinoma | 530344 (50.0%) | |||||
| Squamous Cell Carcinoma | 297015 (28.0%) | |||||
| Other/unknown | 233415 (22.0%) | |||||
aFor colon histology,
Type 1 = Adenocarcinoma + carcinoma + tubulovillous adenocarcinoma + mucinous adenocarcinoma
Type 2 = Neuroendocrine + Other/unknown
bFor RCC histology,
Type 1 = Adenocarcinoma + papillary adenocarcinoma.
Type 2 = Renal cell carcinoma.
Type 3 = Urothelial cell carcinoma + Other/unknown.
cTumor histology for non-small cell lung cancer.